A second asset is AB680 (quemliclustat), a small molecule CD73 antibody running a phase 3 trial in pancreatic cancer. There’s a third molecule, Etrumadenant, and two more, Casdatifan and ...

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner TJ Biopharma ...

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner TJ Biopharma, to ...

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights ...

This is the second China-specific purchase by Sanofi in the last few months. In September, the French pharma acquired China rights to the CD73 antibody uliledlimab from I-Mab spinout TJ Biopharma.

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria. A novel class of antibodies that binds to ...

Recombinant antibody production involves the use of recombinant DNA technology to produce an antibody. In this blog post, you will learn all about the process of recombinant antibody production ...

an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US. For a complete picture of Etrumadenant’s drug-specific PTSR ...

"We found that on average, older adults who are immunocompromised developed fewer antibodies against RSV following vaccination as compared with the very strong responses for healthy people over ...